Published in Nature on July 28, 2005
TGFbeta in Cancer. Cell (2008) 17.44
Endogenous human microRNAs that suppress breast cancer metastasis. Nature (2008) 14.37
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest (2011) 14.22
Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer (2009) 14.17
Tumor metastasis: molecular insights and evolving paradigms. Cell (2011) 10.34
CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature (2011) 8.62
Genes that mediate breast cancer metastasis to the brain. Nature (2009) 8.23
Molecular basis of metastasis. N Engl J Med (2008) 8.19
Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res (2008) 7.65
TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell (2008) 7.60
Tumor self-seeding by circulating cancer cells. Cell (2009) 6.66
HEF1-dependent Aurora A activation induces disassembly of the primary cilium. Cell (2007) 6.50
MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol (2007) 6.41
CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res (2006) 6.35
Parallel progression of primary tumours and metastases. Nat Rev Cancer (2009) 5.55
The metastatic niche: adapting the foreign soil. Nat Rev Cancer (2009) 5.28
Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell (2009) 5.24
AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Res (2010) 4.89
A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell (2012) 4.89
Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst (2010) 4.57
MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer. Cancer Cell (2009) 4.47
Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell (2014) 4.44
Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat Med (2011) 4.25
Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci U S A (2005) 4.20
Tumour exosome integrins determine organotropic metastasis. Nature (2015) 4.09
Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell (2008) 3.95
Metastasis: recent discoveries and novel treatment strategies. Lancet (2007) 3.93
Lung metastasis genes couple breast tumor size and metastatic spread. Proc Natl Acad Sci U S A (2007) 3.92
A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth. PLoS One (2009) 3.86
Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. Nat Med (2011) 3.82
WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell (2009) 3.76
Chemotaxis in cancer. Nat Rev Cancer (2011) 3.68
Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin Cancer Res (2008) 3.67
A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells. Nature (2011) 3.60
A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science (2011) 3.49
Biomechanical remodeling of the microenvironment by stromal caveolin-1 favors tumor invasion and metastasis. Cell (2011) 3.37
Selection of bone metastasis seeds by mesenchymal signals in the primary tumor stroma. Cell (2013) 3.33
Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell (2011) 3.32
Breast cancer: origins and evolution. J Clin Invest (2007) 3.31
Treating metastatic cancer with nanotechnology. Nat Rev Cancer (2011) 3.30
VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging α4β1-positive osteoclast progenitors. Cancer Cell (2011) 3.23
Raf kinase inhibitory protein suppresses a metastasis signalling cascade involving LIN28 and let-7. EMBO J (2009) 3.11
Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends Mol Med (2010) 3.10
Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer (2007) 3.09
Serpins promote cancer cell survival and vascular co-option in brain metastasis. Cell (2014) 3.04
Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer. Nat Med (2012) 2.95
Preparing the "soil": the premetastatic niche. Cancer Res (2006) 2.92
ID genes mediate tumor reinitiation during breast cancer lung metastasis. Proc Natl Acad Sci U S A (2007) 2.85
A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer. Cancer Res (2009) 2.84
The BMP inhibitor Coco reactivates breast cancer cells at lung metastatic sites. Cell (2012) 2.84
Migrastatin analogues target fascin to block tumour metastasis. Nature (2010) 2.84
GOBO: gene expression-based outcome for breast cancer online. PLoS One (2011) 2.81
Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes. Proc Natl Acad Sci U S A (2010) 2.77
Tumor metastasis: moving new biological insights into the clinic. Nat Med (2013) 2.71
Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat Med (2012) 2.66
Macrophage binding to receptor VCAM-1 transmits survival signals in breast cancer cells that invade the lungs. Cancer Cell (2011) 2.64
Unravelling the complexity of metastasis - molecular understanding and targeted therapies. Nat Rev Cancer (2011) 2.64
ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis. Genes Dev (2009) 2.59
Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer. Cancer (2012) 2.59
Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. Oncologist (2013) 2.55
Functional identification of tumor-suppressor genes through an in vivo RNA interference screen in a mouse lymphoma model. Cancer Cell (2009) 2.54
Convergent multi-miRNA targeting of ApoE drives LRP1/LRP8-dependent melanoma metastasis and angiogenesis. Cell (2012) 2.50
Origins of metastatic traits. Cancer Cell (2013) 2.49
Elf5 inhibits the epithelial-mesenchymal transition in mammary gland development and breast cancer metastasis by transcriptionally repressing Snail2. Nat Cell Biol (2012) 2.46
Mouse models of advanced spontaneous metastasis for experimental therapeutics. Nat Rev Cancer (2011) 2.42
HIF-1-dependent expression of angiopoietin-like 4 and L1CAM mediates vascular metastasis of hypoxic breast cancer cells to the lungs. Oncogene (2011) 2.42
A three-gene model to robustly identify breast cancer molecular subtypes. J Natl Cancer Inst (2012) 2.34
Breast cancer methylomes establish an epigenomic foundation for metastasis. Sci Transl Med (2011) 2.33
Synergistic response to oncogenic mutations defines gene class critical to cancer phenotype. Nature (2008) 2.32
Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer. Breast Cancer Res (2007) 2.32
Mechanistic links between COPD and lung cancer. Nat Rev Cancer (2013) 2.28
T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res (2009) 2.26
Microenvironmental regulation of cancer development. Curr Opin Genet Dev (2008) 2.25
Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development. J Exp Med (2007) 2.25
Targeting androgen receptor in estrogen receptor-negative breast cancer. Cancer Cell (2011) 2.23
MYC regulation of a "poor-prognosis" metastatic cancer cell state. Proc Natl Acad Sci U S A (2010) 2.21
Modulated Expression of Specific tRNAs Drives Gene Expression and Cancer Progression. Cell (2016) 2.19
Control of cyclin D1 and breast tumorigenesis by the EglN2 prolyl hydroxylase. Cancer Cell (2009) 2.15
Postpartum mammary gland involution drives progression of ductal carcinoma in situ through collagen and COX-2. Nat Med (2011) 2.12
Identification of a pharmacologically tractable Fra-1/ADORA2B axis promoting breast cancer metastasis. Proc Natl Acad Sci U S A (2013) 2.12
A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the proliferation, immune response and RNA splicing modules in breast cancer. Breast Cancer Res (2008) 2.09
Transcriptomic dissection of tongue squamous cell carcinoma. BMC Genomics (2008) 2.09
CCL2-induced chemokine cascade promotes breast cancer metastasis by enhancing retention of metastasis-associated macrophages. J Exp Med (2015) 2.05
Paradoxical relationship between chromosomal instability and survival outcome in cancer. Cancer Res (2011) 2.05
Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer. Hepatology (2008) 2.04
Endogenous tRNA-Derived Fragments Suppress Breast Cancer Progression via YBX1 Displacement. Cell (2015) 2.01
Pan-cancer genetic analysis identifies PARK2 as a master regulator of G1/S cyclins. Nat Genet (2014) 2.01
Anchorage-independent cell growth signature identifies tumors with metastatic potential. Oncogene (2009) 1.99
Gene expression changes in an animal melanoma model correlate with aggressiveness of human melanoma metastases. Mol Cancer Res (2008) 1.99
Isotopic labeling of terminal amines in complex samples identifies protein N-termini and protease cleavage products. Nat Biotechnol (2010) 1.98
KLF17 is a negative regulator of epithelial-mesenchymal transition and metastasis in breast cancer. Nat Cell Biol (2009) 1.97
Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse. Breast Cancer Res Treat (2011) 1.96
PBX1 genomic pioneer function drives ERα signaling underlying progression in breast cancer. PLoS Genet (2011) 1.93
Amphiregulin exosomes increase cancer cell invasion. Curr Biol (2011) 1.93
Growth factor stimulation induces a distinct ER(alpha) cistrome underlying breast cancer endocrine resistance. Genes Dev (2010) 1.92
Prognostic and predictive value of a malignancy-risk gene signature in early-stage non-small cell lung cancer. J Natl Cancer Inst (2011) 1.92
Metastatic stem cells: sources, niches, and vital pathways. Cell Stem Cell (2014) 1.88
The fibromatosis signature defines a robust stromal response in breast carcinoma. Lab Invest (2008) 1.85
A compact VEGF signature associated with distant metastases and poor outcomes. BMC Med (2009) 1.84
CAS proteins in normal and pathological cell growth control. Cell Mol Life Sci (2009) 1.84
Molecular portraits of human breast tumours. Nature (2000) 94.14
Gene expression profiling predicts clinical outcome of breast cancer. Nature (2002) 71.36
A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med (2002) 58.15
Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell (2004) 31.38
Untangling the ErbB signalling network. Nat Rev Mol Cell Biol (2001) 28.05
New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer (2002) 24.71
The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer (2003) 22.78
A molecular signature of metastasis in primary solid tumors. Nat Genet (2002) 21.36
Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med (2002) 21.28
Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer (2002) 17.49
A multigenic program mediating breast cancer metastasis to bone. Cancer Cell (2003) 16.86
Cancer and the chemokine network. Nat Rev Cancer (2004) 10.27
Genomic analysis of metastasis reveals an essential role for RhoC. Nature (2000) 10.11
A progression puzzle. Nature (2002) 9.56
Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest (2005) 6.10
Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization. In Vitro (1978) 4.67
Id proteins in development, cell cycle and cancer. Trends Cell Biol (2003) 4.53
Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res (2000) 3.41
A novel triple-modality reporter gene for whole-body fluorescent, bioluminescent, and nuclear noninvasive imaging. Eur J Nucl Med Mol Imaging (2004) 3.07
SPARC and tumor growth: where the seed meets the soil? J Cell Biochem (2004) 2.75
Probabilities of death from breast cancer and other causes among female breast cancer patients. J Natl Cancer Inst (2004) 2.60
Tumor progression and metastasis. Carcinogenesis (2000) 2.57
Enhanced interleukin (IL)-13 responses in mice lacking IL-13 receptor alpha 2. J Exp Med (2003) 2.54
Metastatic potential: generic predisposition of the primary tumor or rare, metastatic variants-or both? Cell (2003) 2.52
Tissue-wide expression profiling using cDNA subtraction and microarrays to identify tumor-specific genes. Cancer Res (2004) 2.36
Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis. Breast Cancer Res Treat (2000) 2.33
Diagnostic and prognostic prediction using gene expression profiles in high-dimensional microarray data. Br J Cancer (2003) 2.08
The role of COX-2 inhibition in breast cancer treatment and prevention. Semin Oncol (2004) 2.04
Epiregulin is a potent pan-ErbB ligand that preferentially activates heterodimeric receptor complexes. J Biol Chem (1998) 1.81
Soluble adhesion molecules (E-selectin, ICAM-1 and VCAM-1) in breast carcinoma. Eur J Cancer (2002) 1.79
Clinical progression of breast cancer malignant behavior: what to expect and when to expect it. J Clin Oncol (2000) 1.78
Helix-loop-helix proteins in mammary gland development and breast cancer. J Mammary Gland Biol Neoplasia (2003) 1.57
Altered expression of metastasis-associated and regulatory molecules in effusions from breast cancer patients: a novel model for tumor progression. Clin Cancer Res (2004) 1.44
Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell (2003) 25.94
Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61
Cancer metastasis: building a framework. Cell (2006) 19.67
A multigenic program mediating breast cancer metastasis to bone. Cancer Cell (2003) 16.86
Endogenous human microRNAs that suppress breast cancer metastasis. Nature (2008) 14.37
A faster circular binary segmentation algorithm for the analysis of array CGH data. Bioinformatics (2007) 14.25
Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer (2009) 14.17
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A (2007) 11.85
Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med (2012) 10.20
Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med (2008) 10.12
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature (2012) 8.66
Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer (2003) 8.35
Genes that mediate breast cancer metastasis to the brain. Nature (2009) 8.23
Molecular basis of metastasis. N Engl J Med (2008) 8.19
TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell (2008) 7.60
Epithelial-mesenchymal transitions: twist in development and metastasis. Cell (2004) 7.14
Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature (2007) 7.05
Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. Nature (2009) 7.04
Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol (2004) 6.95
(V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci U S A (2009) 6.78
Genome sequencing identifies a basis for everolimus sensitivity. Science (2012) 6.71
Tumor self-seeding by circulating cancer cells. Cell (2009) 6.66
The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci U S A (2010) 6.54
Genetic determinants of cancer metastasis. Nat Rev Genet (2007) 6.38
Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell (2004) 6.35
Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest (2005) 6.10
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet (2010) 6.10
A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med (2013) 6.09
Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci U S A (2010) 5.59
Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet (2009) 5.31
Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature (2002) 5.25
Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell (2009) 5.24
Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest (2007) 5.17
Vancomycin-resistant Enterococcus domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans. J Clin Invest (2010) 4.95
Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med (2011) 4.91
A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell (2012) 4.89
Nuclear CDKs drive Smad transcriptional activation and turnover in BMP and TGF-beta pathways. Cell (2009) 4.81
Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33. Proc Natl Acad Sci U S A (2008) 4.76
Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest (2004) 4.59
TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell (2005) 4.46
Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res (2002) 4.42
Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest (2006) 4.37
Roles of TGFbeta in metastasis. Cell Res (2009) 4.35
Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat Med (2011) 4.25
Integrative clustering of multiple genomic data types using a joint latent variable model with application to breast and lung cancer subtype analysis. Bioinformatics (2009) 4.21
Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci U S A (2005) 4.20
Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest (2008) 4.13
Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med (2011) 4.10
An X chromosome gene, WTX, is commonly inactivated in Wilms tumor. Science (2007) 4.00
Lung metastasis genes couple breast tumor size and metastatic spread. Proc Natl Acad Sci U S A (2007) 3.92
Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol (2011) 3.92
Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet (2011) 3.91
E2F4/5 and p107 as Smad cofactors linking the TGFbeta receptor to c-myc repression. Cell (2002) 3.87
Oncogenic cooperation and coamplification of developmental transcription factor genes in lung cancer. Proc Natl Acad Sci U S A (2007) 3.84
Interlaboratory comparability study of cancer gene expression analysis using oligonucleotide microarrays. Clin Cancer Res (2005) 3.79
WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell (2009) 3.76
Oncogenic Ras and Akt signaling contribute to glioblastoma formation by differential recruitment of existing mRNAs to polysomes. Mol Cell (2003) 3.68
Beyond tumorigenesis: cancer stem cells in metastasis. Cell Res (2007) 3.63
Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc Natl Acad Sci U S A (2003) 3.61
A self-enabling TGFbeta response coupled to stress signaling: Smad engages stress response factor ATF3 for Id1 repression in epithelial cells. Mol Cell (2003) 3.57
Methylation of a histone mimic within the histone methyltransferase G9a regulates protein complex assembly. Mol Cell (2007) 3.51
A gene expression signature predicts survival of patients with stage I non-small cell lung cancer. PLoS Med (2006) 3.37
AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. Cell Metab (2012) 3.35
Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet (2012) 3.33
Selection of bone metastasis seeds by mesenchymal signals in the primary tumor stroma. Cell (2013) 3.33
Relationship of gene expression and chromosomal abnormalities in colorectal cancer. Cancer Res (2006) 3.32
Hematopoiesis controlled by distinct TIF1gamma and Smad4 branches of the TGFbeta pathway. Cell (2006) 3.31
Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol (2008) 3.30
VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging α4β1-positive osteoclast progenitors. Cancer Cell (2011) 3.23
Balancing BMP signaling through integrated inputs into the Smad1 linker. Mol Cell (2007) 3.23
Is cancer a disease of self-seeding? Nat Med (2006) 3.19
Polycomb group protein ezh2 controls actin polymerization and cell signaling. Cell (2005) 3.01
Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer. Nat Med (2012) 2.95
Dependency of colorectal cancer on a TGF-β-driven program in stromal cells for metastasis initiation. Cancer Cell (2012) 2.94
C/EBPbeta at the core of the TGFbeta cytostatic response and its evasion in metastatic breast cancer cells. Cancer Cell (2006) 2.87
The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell (2008) 2.87
Profound alterations of intestinal microbiota following a single dose of clindamycin results in sustained susceptibility to Clostridium difficile-induced colitis. Infect Immun (2011) 2.87